表紙
市場調查報告書

人類乳突病毒(HPV)及巨細胞病毒(CMV)治療藥的全球市場 - 規模,佔有率,展望,及機會分析

Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

出版商 Coherent Market Insights 商品編碼 883785
出版日期 內容資訊 英文 167 Pages
商品交期: 2-3個工作天內
價格
Back to Top
人類乳突病毒(HPV)及巨細胞病毒(CMV)治療藥的全球市場 - 規模,佔有率,展望,及機會分析 Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
出版日期: 2019年06月14日內容資訊: 英文 167 Pages
簡介

這份報告提供全球人類乳突病毒(HPV)及巨細胞病毒(CMV)治療藥市場的相關調查,提供市場成長及阻礙因素,各藥物種類·用途·流通管道·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 研究的目的及假設

  • 研究目的
  • 假設
  • 簡稱

第2章 市場概要

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 藥物類別
    • 各用途
    • 各流通管道
    • 各地區
  • COM (Coherent Opportunity Map)

第3章 市場動態,法規及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的開發
  • 流行病學
  • 技術的進步
  • 專利分析
  • 附著率
  • 產品交換器(美國)
  • 歷史概要
  • 合併和收購
  • 法規及償付方案
  • 波特的五力分析
  • PEST分析

第4章 全球人類乳突病毒(HPV)及巨細胞病毒(CMV)治療藥市場:藥物類別

  • 簡介
  • HPV治療藥
  • 白細胞介素
  • 細胞激素
  • 趨化素
  • TCA
  • CMV治療藥

第5章 全球人類乳突病毒(HPV)及巨細胞病毒(CMV)治療藥市場:各用途

  • 簡介
  • HPV治療用
  • CMV治療用

第6章 全球人類乳突病毒(HPV)及巨細胞病毒(CMV)治療藥市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球人類乳突病毒(HPV)及巨細胞病毒(CMV)治療藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第8章 競爭情形

  • 熱圖分析
  • 企業簡介
    • GlaxoSmithKline
    • ALLERGAN
    • Bausch Health
    • Lee's Pharmaceuticals Holdings
    • Merck Sharp & Dohme
    • Fougera Pharmaceuticals
    • Clinigen Group plc.
    • Perrigo Company plc.
    • Roche Holdings AG
    • Fresenius Kabi
  • 分析師的意見

第9章 章節

  • 參考文獻
  • 調查方法
  • 本公司與銷售方面

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Cytomegalovirus (CMV) infections spread through body fluids such as saliva, semen, breast milk, and urine. Signs and symptoms of the infections include, fatigue, fever, diarrhea, pneumonia, and hepatitis, shortness of breath, gastrointestinal ulceration, and bleeding.

Although no treatment for the infection caused by human papillomavirus (HPV) is available, symptoms can be treated. Most sexually active men and women suffer from HPV infections. The infections spread through oral, vaginal or anal sex. HPV can also be transmitted during birth to infant and can lead to genital or respiratory infections.

Market Dynamics:

Increasing collaboration activities of major players is expected to propel growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market. For instance, in November 2018, GeoVax Labs Inc. announced collaboration with Virometix. The collaboration focuses on development of therapeutic vaccines for HPV infections. This collaboration will include preclinical animal testing of GeoVax's MVA-Vectored HPV vaccines candidates in combination with Virometix synthetic HPV vaccines candidates.

Moreover, increasing regulatory approvals for novel therapies is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in November 2017, Merck received the U.S. Food and Drug Administration approval for its Prevymis (letermovir) tablets and intravenous (IV) injection for prophylaxis of CMV infections and CMV seropositive recipients.

Key features of the study:

  • This report provides in-depth analysis of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, , Allergan, Bausch Health, GlaxoSmithKline, Lee's Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for anesthesia device market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Drug Type:
  • HPV Therapeutics
    • Immunomodulatory Agents
  • Interleukins
  • Cytokines
  • Chemokine
  • Others
    • Keratolytic Agents
  • TCA (Trichloroacetic Acid)
  • Bichloracetic Acid
    • Anti-neoplastic Agents
    • Sinecatechins
  • CMV Therapeutics
    • Ganciclovir/Valganciclovir
    • Foscarnet
    • Cidifovir
  • Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Application:
  • HPV Therapeutics Application
    • Genital warts
    • Cervical cancer
    • Epidermodysplasia Verrucifdormis
    • Others
  • CMV Therapeutics Application
    • CMV Retinitis
    • Pneumonia
    • Gastrointestinal ulcers
    • Encephalitis
    • Others
  • Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Region:
  • North America
  • By Country:
    • U.S.
    • Canada
  • By Drug Type:
    • HPV Therapeutics
  • Immunomodulatory Agents
  • Interleukins
  • Cytokines
  • Chemokine
  • Others
  • Keratolytic Agents
  • TCA (Trichloroacetic Acid)
  • Bichloracetic Acid
  • Anti-neoplastic Agents
  • Sinecatechins
    • CMV Therapeutics
  • Ganciclovir/Valganciclovir
  • Foscarnet
  • Cidifovir
  • By Application
    • HPV Therapeutics Application
  • Genital warts
  • Cervical cancer
  • Epidermodysplasia Verrucifdormis
  • Others
    • CMV Therapeutics Application
  • CMV Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Others
  • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Europe
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • By Drug Type:
    • HPV Therapeutics
  • Immunomodulatory Agents
  • Interleukins
  • Cytokines
  • Chemokine
  • Others
  • Keratolytic Agents
  • TCA (Trichloroacetic Acid)
  • Bichloracetic Acid
  • Anti-neoplastic Agents
  • Sinecatechins
    • CMV Therapeutics
  • Ganciclovir/Valganciclovir
  • Foscarnet
  • Cidifovir
  • By Application
    • HPV Therapeutics Application
  • Genital warts
  • Cervical cancer
  • Epidermodysplasia Verrucifdormis
  • Others
    • CMV Therapeutics Application
  • CMV Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Others
  • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Asia Pacific
  • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • By Drug Type:
    • HPV Therapeutics
  • Immunomodulatory Agents
  • Interleukins
  • Cytokines
  • Chemokine
  • Others
  • Keratolytic Agents
  • TCA (Trichloroacetic Acid)
  • Bichloracetic Acid
  • Anti-neoplastic Agents
  • Sinecatechins
    • CMV Therapeutics
  • Ganciclovir/Valganciclovir
  • Foscarnet
  • Cidifovir
  • By Application
    • HPV Therapeutics Application
  • Genital warts
  • Cervical cancer
  • Epidermodysplasia Verrucifdormis
  • Others
    • CMV Therapeutics Application
  • CMV Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Others
  • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Latin America
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • By Drug Type:
    • HPV Therapeutics
  • Immunomodulatory Agents
  • Interleukins
  • Cytokines
  • Chemokine
  • Others
  • Keratolytic Agents
  • TCA (Trichloroacetic Acid)
  • Bichloracetic Acid
  • Anti-neoplastic Agents
  • Sinecatechins
    • CMV Therapeutics
  • Ganciclovir/Valganciclovir
  • Foscarnet
  • Cidifovir
  • By Application
    • HPV Therapeutics Application
  • Genital warts
  • Cervical cancer
  • Epidermodysplasia Verrucifdormis
  • Others
    • CMV Therapeutics Application
  • CMV Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Others
  • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Middle East
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • By Drug Type:
    • HPV Therapeutics
  • Immunomodulatory Agents
  • Interleukins
  • Cytokines
  • Chemokine
  • Others
  • Keratolytic Agents
  • TCA (Trichloroacetic Acid)
  • Bichloracetic Acid
  • Anti-neoplastic Agents
  • Sinecatechins
    • CMV Therapeutics
  • Ganciclovir/Valganciclovir
  • Foscarnet
  • Cidifovir
  • By Application
    • HPV Therapeutics Application
  • Genital warts
  • Cervical cancer
  • Epidermodysplasia Verrucifdormis
  • Others
    • CMV Therapeutics Application
  • CMV Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Others
  • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Africa
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • By Drug Type:
    • HPV Therapeutics
  • Immunomodulatory Agents
  • Interleukins
  • Cytokines
  • Chemokine
  • Others
  • Keratolytic Agents
  • TCA (Trichloroacetic Acid)
  • Bichloracetic Acid
  • Anti-neoplastic Agents
  • Sinecatechins
    • CMV Therapeutics
  • Ganciclovir/Valganciclovir
  • Foscarnet
  • Cidifovir
  • By Application
    • HPV Therapeutics Application
  • Genital warts
  • Cervical cancer
  • Epidermodysplasia Verrucifdormis
  • Others
    • CMV Therapeutics Application
  • CMV Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Others
  • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
  • GlaxoSmithKline*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Allergan
  • Bausch Health
  • Lee's Pharmaceutical Holdings
  • Merck Sharp & Dohme
  • Fougera Pharmaceuticals
  • Clinigen Group plc.
  • Perrigo Company plc.
  • Roche Holding AG
  • Biotest AG
  • Fresenius Kabi

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Epidemiology
  • Technology Advancements
  • Patent Analysis
  • Adherence Rate
  • Product Switch (U.S.)
  • Historical Overview
  • Merger and Acquisition
  • Regulatory and Reimbursement Scenario
  • PORTER'S Five Forces
  • PEST Analysis

4. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market By Drug Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • HPV Therapeutics
    • Immunomodulatory Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Interleukins
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Cytokines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Chemokine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Keratolytic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • TCA
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Bichloracetic Acid
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Anti-neoplastic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Sinecatechins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • CMV Therapeutics
    • Ganciclovir/ Valaganciclovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Foscarnet
    • Introduction
    • Market Size and Forecast , and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Cidifovir
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, By Application, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • HPV Therapeutics Application
    • Genital warts
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Cervical cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Epidermodysplasia Verrucifdormis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • CMV Therapeutics Application
    • CMV Retinitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Pneumonia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Gastrointestinal ulcers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Encephalitis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market, By Distribution Chanel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • GlaxoSmithKline
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • ALLERGAN
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bausch Health
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lee's Pharmaceuticals Holdings
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck Sharp & Dohme
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Fougera Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Clinigen Group plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Perrigo Company plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Roche Holdings AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Fresenius Kabi
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top